Cover Image
市場調查報告書

腫瘤壞死因子受體超級家族成員4 (ACT35抗體/TAX轉印活性糖蛋白質1受體/CD134/TNFRSF4):開發中產品分析

Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 363119
出版日期 內容資訊 英文 56 Pages
訂單完成後即時交付
價格
Back to Top
腫瘤壞死因子受體超級家族成員4 (ACT35抗體/TAX轉印活性糖蛋白質1受體/CD134/TNFRSF4):開發中產品分析 Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Pipeline Review, H2 2017
出版日期: 2017年08月08日 內容資訊: 英文 56 Pages
簡介

本報告提供全球各國的腫瘤壞死因子受體超級家族成員4 (ACT35抗體/TAX轉印活性糖蛋白質1受體/CD134/TNFRSF4) 治療用的開發中產品的開發情形相關分析,產品開發、上市的最新趨勢,及臨床實驗的各階段的產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊,為您概述為以下內容。

目錄

  • 簡介
    • 分析範圍
  • 腫瘤壞死因子受體超級家族成員4 (ACT35抗體/TAX轉印活性糖蛋白質1受體/CD134/TNFRSF4)的概要
  • 治療藥的開發
    • 臨床實驗的各階段
    • 各治療領域
    • 各症狀
  • 開發中產品的概要
    • 初期階段的產品
  • 各企業開發中的治療藥
  • 治療藥的評估
    • 單劑治療藥/並用治療藥的情況
    • 各作用機制
    • 各投藥法
    • 各分子類型
  • 開發治療藥的企業
    • Alligator Bioscience AB
    • Apogenix GmbH
    • BioInvent International AB
    • Bristol-Myers Squibb Company
    • Enumeral Biomedical Holdings, Inc.
    • Genentech, Inc.
    • GlaxoSmithKline Plc
    • MedImmune, LLC
    • Pfizer Inc.
  • 藥物簡介
    • ADC-1015
      • 產品概要
      • 作用機制
      • 研究開發 (R&D)的發展情形
    • BMS-986178
    • Delta-24-RGDOX
    • durvalumab + MEDI-6383
    • GSK-3174998
    • MEDI-0562
    • MEDI-6383
    • 腫瘤OX40工作用單株抗體
    • 腫瘤OX40工作用單株抗體
    • PF-04518600
    • 固體腫瘤OX40工作用基因改造蛋白質
    • 第一型糖尿病OX40、Notch 3工作用基因改造蛋白質
    • RG-7888
  • 開發暫停的產品
  • 開發中止的產品
  • 值得注意的最新趨勢、新聞稿 (共3件)
  • 附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC0958TDB

Summary:

Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Tumor Necrosis Factor Receptor Superfamily Member 4 or OX40 is a member of the TNF-receptor superfamily. This receptor has been shown to activate NF-kappaB through its interaction with adaptor proteins TRAF2 and TRAF5. OX40L binds to OX40 receptors on T-cells, preventing them from dying and subsequently increasing cytokine production. OX40 has a critical role in the maintenance of an immune response. OX40 also plays a crucial role in both Th1 and Th2 mediated reactions.

Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) pipeline Target constitutes close to 17 molecules. Out of which approximately 17 molecules are developed by Companies. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 5, 3, 5 and 4 respectively. Report covers products from therapy areas Oncology, Immunology, Dermatology, Gastrointestinal and Metabolic Disorders which include indications Solid Tumor, Head And Neck Cancer Squamous Cell Carcinoma, Non-Small Cell Lung Cancer, Bladder Cancer, Melanoma, Renal Cell Carcinoma, Atopic Dermatitis, Breast Cancer, Cervical Cancer, Colorectal Cancer, Endometrial Cancer, Gastric Cancer, Graft Versus Host Disease (GVHD), Hematological Tumor, Metastatic Cancer, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Melanoma, Metastatic Ovarian Cancer, Metastatic Renal Cell Carcinoma, Soft Tissue Sarcoma, Systemic Lupus Erythematosus, Transplant Rejection, Type 1 Diabetes (Juvenile Diabetes) and Ulcerative Colitis.

The latest report Tumor Necrosis Factor Receptor Superfamily Member 4 - Pipeline Review, H2 2017, outlays comprehensive information on the Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4)
  • The report reviews Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Overview
    • Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
  • Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Companies Involved in Therapeutics Development
    • Abeome Corp
    • Alligator Bioscience AB
    • Apogenix GmbH
    • BioInvent International AB
    • Bristol-Myers Squibb Company
    • Denceptor Therapeutics Ltd
    • Enumeral Biomedical Holdings Inc
    • GlaxoSmithKline Plc
    • Glenmark Pharmaceuticals Ltd
    • Incyte Corp
    • Kyowa Hakko Kirin Co Ltd
    • MedImmune LLC
    • Pfizer Inc
  • Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Drug Profiles
    • ATOR-1015 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BMS-986178 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • durvalumab + MEDI-0562 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ENUM-004 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Fusion Proteins to Agonize OX40 and NOTCH1 for Type 1 Diabetes - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GBR-8383 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GSK-3174998 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • INCAGN-1949 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KHK-4083 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MEDI-0562 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MEDI-0562 + tremelimumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibodies to Agonize OX40 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody Conjugate to Target OX40L for Transplant Rejection - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Agonize OX40L Receptor for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PF-04518600 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein to Agonize OX40 for Solid Tumor - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ZL-1101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Dormant Products
  • Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Discontinued Products
  • Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Product Development Milestones
    • Featured News & Press Releases
      • Jul 08, 2017: Alligator contracts BioInvent for process development and cGMP manufacturing of the immuno-oncology drug candidate ADC-1015
      • May 04, 2017: Alligator Bioscience presents promising immuno-oncology data at US conference; - Strong new preclinical findings for ATOR-1015
      • Apr 28, 2017: Alligator Bioscience to present new pre-clinical data for ATOR-1015 at PEGS conference in Boston, May 4
      • Mar 07, 2017: Agenus Abstract Accepted for Presentation on INCAGN01949 at the American Association for Cancer Research (AACR) 2017 Annual Meeting
      • Nov 30, 2016: Agenus Announces Commencement of Phase 1/2 Clinical Trial of anti-OX40 Checkpoint Antibody INCAGN1949 in Patients with Solid Tumors
      • Apr 18, 2016: Agenus Presents Poster on Checkpoint Antibody Product Candidate INCAGN-1949 at the American Association for Cancer Research (AACR) 2016 Annual Meeting
      • Nov 03, 2015: GSK and Merck to study immunotherapy combination as potential cancer treatment
      • Sep 21, 2011: AgonOx Receives US Patent For OX40 Ligand Fusion Proteins And Use In Cancer Therapy
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Indications, H2 2017
  • Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Pipeline by Abeome Corp, H2 2017
  • Pipeline by Alligator Bioscience AB, H2 2017
  • Pipeline by Apogenix GmbH, H2 2017
  • Pipeline by BioInvent International AB, H2 2017
  • Pipeline by Bristol-Myers Squibb Company, H2 2017
  • Pipeline by Denceptor Therapeutics Ltd, H2 2017
  • Pipeline by Enumeral Biomedical Holdings Inc, H2 2017
  • Pipeline by GlaxoSmithKline Plc, H2 2017
  • Pipeline by Glenmark Pharmaceuticals Ltd, H2 2017
  • Pipeline by Incyte Corp, H2 2017
  • Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2017
  • Pipeline by MedImmune LLC, H2 2017
  • Pipeline by Pfizer Inc, H2 2017
  • Dormant Projects, H2 2017
  • Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Top 10 Indications, H2 2017
  • Number of Products by Mechanism of Actions, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top